MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$3,587K
EPS
-$0.08
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-06-30
2025-03-31
Total revenues
--69 -
Total revenues
86 117* 100 202
Research and development
817 2,683* 4,881 6,124
General and administrative
3,085 2,075* 2,730 3,275
Total operating expenses
3,902 4,757* 7,611 9,399
Operating loss
-3,816 -4,640* -7,542 -9,197
Other income, net
231 -566* 1,795 594
Loss from continuing operations before income taxes
-3,585 -5,207* -5,747 -8,603
Income tax expense
0 4* 0 -
Loss from continuing operations
-3,585 -5,211* -5,747 -8,603
Product sales, net-Product
-282* --
General and administrative
-5 --
Total operating expenses
-5* --
Income (loss) from discontinued operations, before taxes
-277* --
Income tax expense
-0* --
Loss from discontinued operations, net of income taxes
0 277* -8 -8
Net loss
-3,585 -4,934* -5,755 -8,611
Unrealized gaines on marketable securities, net of tax of 0
-2 15 -2 -20
Total other comprehensive gain
-2 15* -2 -20
Comprehensive loss
-3,587 -4,919 -5,757 -8,631
Basic EPS
-0.08 -0.115 -0.13 -0.2
Diluted EPS
-0.08 -0.115 -0.13 -0.2
Basic Average Shares
42,768,000 42,872,000 42,759,000 42,673,000
Diluted Average Shares
42,768,000 42,872,000 42,759,000 42,673,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$3,587K (58.44%↑ Y/Y)Net loss-$3,585K (58.37%↑ Y/Y)Total othercomprehensive gain-$2K (90.00%↑ Y/Y)Loss from continuingoperations-$3,585K (58.33%↑ Y/Y)Unrealized gaines onmarketable securities, net...-$2K (90.00%↑ Y/Y)General andadministrative$3,085K (-5.80%↓ Y/Y)Other segment items$473K (-53.90%↓ Y/Y)Research anddevelopment-Research And Development...$194K (-92.30%↓ Y/Y)Research anddevelopment-Repibresib VYN201$150K (-94.18%↓ Y/Y)Loss from continuingoperations before income...-$3,585K (58.33%↑ Y/Y)Other income, net$231K (-61.11%↓ Y/Y)Total operatingexpenses$3,902K (-58.48%↓ Y/Y)Operating loss-$3,816K (58.51%↑ Y/Y)Total revenues$86K (-57.43%↓ Y/Y)Operating loss-$3,816K (58.51%↑ Y/Y)Total operatingexpenses$3,902K (-58.48%↓ Y/Y)General andadministrative$3,085K (-5.80%↓ Y/Y)Research and development$817K (-86.66%↓ Y/Y)

VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Inc. (VYNE)